JANET TROGDON: Open Payments
NPI 1487816104 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$233 in 12 payments from 8 companies in 2025. Trend: 2023 $551 · 2024 $579 · 2025 $233
Food & beverage: $233
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $46 |
| Neurocrine BioSciences, Inc. | 2 | $42 |
| Vanda Pharmaceuticals Inc. | 2 | $41 |
| ABBVIE INC. | 2 | $30 |
| Organon LLC | 1 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Janssen Pharmaceuticals, Inc | 1 | $15 |
Products named: CAPLYTA, INGREZZA, FANAPT, VRAYLAR, NEXPLANON, Qelbree, REXULTI, SPRAVATO.
Industry payments across OK — which companies pay providers there.
